This funding augments the previously announced $15 million Series D financing.
AxioMed's Freedom Lumbar Disc is currently on the market in the EU and advancing toward completion of its Investigational Device Exemption pivotal study in the U.S. AxioMed intends to follow a similar regulatory and marketing pathway as the FLD with its Freedom Cervical Disc, which recently received a CE Mark for introduction in the EU.
Related Articles on Spine Devices:
20 Spine Devices Receive FDA 510(k) Clearance in May
Korean FDA Approves Mazor Robotics' Renaissance Robotic Platform